Entrectinib Shrank NTRK Fusion-Positive Solid Tumors
More than half of patients with central nervous system metastases responded to the drug.
Diagnosis & Disease Information
20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
A 20-year follow-up demonstrated a continued survival benefit with HDCT with HSCT for patients with early breast cancer and at least 9 involved axial lymph nodes.
Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
Cabozantinib demonstrated efficacy in osteosarcoma and Ewing sarcoma in 2 single-arm, phase 2 trials, with objective response rates of 45% and 58%, respectively.
Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
Six months of treatment with trastuzumab is substantially more cost-effective than 12 months of therapy.
Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
The 2 most common resistance mechanisms were MET amplification, EGFR C797S mutation.
Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
The drug combination was particularly beneficial for patients in the PD-L1-positive subgroup.
Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
The regimen did not improve survival and increased bone fractures.
Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
Brigatinib significantly delayed time to intracranial progression and prolonged PFS compared with crizotinib in patients with ALK+ NSCLC with intracranial metastases.
Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.
Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker’s phase 3 trial.
- Loading...
Loading...
Next post in ESMO 2018
Loading... 
Loading...